Abstract
Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Keywords: Zolpidem, driving, accidents, compliance
Current Drug Safety
Title: Zolpidem and Traffic Safety - The Importance of Treatment Compliance
Volume: 2 Issue: 3
Author(s): Joris C. Verster, Edmund R. Volkerts, Berend Olivier, William Johnson and Laura Liddicoat
Affiliation:
Keywords: Zolpidem, driving, accidents, compliance
Abstract: Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Export Options
About this article
Cite this article as:
Verster C. Joris, Volkerts R. Edmund, Olivier Berend, Johnson William and Liddicoat Laura, Zolpidem and Traffic Safety - The Importance of Treatment Compliance, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668882
DOI https://dx.doi.org/10.2174/157488607781668882 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Biological Drugs for the Treatment of Uncontrolled Severe Asthma in Children
Current Pediatric Reviews Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms
Current Medicinal Chemistry Breaking the Skin Barrier: Achievements and Future Directions
Current Pharmaceutical Design The Myometrium in Pregnant Women with Obesity
Current Vascular Pharmacology The Mechanistic Role of Different Mediators in the Pathophysiology of Nephropathy: A Review
Current Drug Targets Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma
Combinatorial Chemistry & High Throughput Screening Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids
Current Medicinal Chemistry Vitamin D and Acute Respiratory Tract Infection
Current Respiratory Medicine Reviews Editorial: Pharmacotherapy of Alcohol Dependence: Past, Present and Future Research
Current Pharmaceutical Design Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy
Current Drug Metabolism Diagnostic Value of Chest X-Ray in Febrile Patients without Localizing Signs or Symptoms at the Emergency Department
Current Medical Imaging Astragalin Attenuates UVB Radiation-induced Actinic Keratosis Formation
Anti-Cancer Agents in Medicinal Chemistry Novel Thioester Prodrug of N-acetylcysteine for Odor Masking and Bioavailability Enhancement
Current Drug Delivery Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drugs Acting on Mast Cells Functions: A Cell Biological Perspective
Inflammation & Allergy - Drug Targets (Discontinued) IL-22 Produced by T helper Cell 22 as a New player in the Pathogenesis of Immune Thrombocytopenia
Endocrine, Metabolic & Immune Disorders - Drug Targets